GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (LTS:0HKD) » Definitions » Debt-to-Revenue

Axogen (LTS:0HKD) Debt-to-Revenue : 0.40 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Axogen Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Axogen's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.5 Mil. Axogen's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $67.7 Mil. Axogen's annualized Revenue for the quarter that ended in Dec. 2023 was $171.7 Mil. Axogen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.40.


Axogen Debt-to-Revenue Historical Data

The historical data trend for Axogen's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axogen Debt-to-Revenue Chart

Axogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.48 0.53 0.49 0.44

Axogen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.46 0.44 0.41 0.40

Competitive Comparison of Axogen's Debt-to-Revenue

For the Medical Devices subindustry, Axogen's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axogen's Debt-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Axogen's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Axogen's Debt-to-Revenue falls into.



Axogen Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Axogen's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.547 + 67.745) / 159.012
=0.44

Axogen's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.547 + 67.745) / 171.688
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.


Axogen Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Axogen's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Axogen (LTS:0HKD) Business Description

Traded in Other Exchanges
Address
13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Axogen (LTS:0HKD) Headlines

No Headlines